

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Raphael GORODETSKY et al.

Confirmation No.: 3576

Patent No.: 7,122,620 B1

Application No.: 09/487,790

Patent Date: October 17, 2006

Filing Date: January 20, 2000

For: HAPTOTACTIC PEPTIDES

Attorney Docket No.: 85189-5700

REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 C.F.R. § 1.322

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Patentees hereby respectfully request the issuance of a Certificate of Correction in connection with the above-identified patent. The correction is listed on the attached Form PTO-1050. The correction requested is as follows:

Title Page:

Item (73) Assignee, before "**Medical Research Services and Development Ltd.**" insert -- **Hadasit** --. The name of the assignee will then correctly appear as "**Hadasit Medical Research Services and Development Ltd.**" Support for this change appears on the Request for Correction of Form PTOL-85 filed July 12, 2006.

The requested correction is for an error that appears to have been made by the Office. Therefore, no fee is believed to be due for this request. Should any fees be required, however, please charge such fees to Winston & Strawn LLP Deposit Account No. 50-1814. Please issue a Certificate of Correction in due course.

Respectfully submitted,

Date

10/31/06



Allan A. Fanucci, Reg. No. 30,256

WINSTON & STRAWN LLP
Customer No. 28765

212-294-3311

**UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION**

PATENT NO.: 7,122,620 B1
APPLICATION NO.: 09/487,790
DATED: Oct. 17, 2006
INVENTOR(S): Gorodetsky et al.

Page 1 of 1

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Title Page:

Item (73) Assignee, before “**Medical Research Services and Development Ltd.**” insert -- **Hadasit** --.



US007122620B1

(12) **United States Patent**
Gorodetsky et al.(10) **Patent No.:** **US 7,122,620 B1**(45) **Date of Patent:** **Oct. 17, 2006**(54) **HAPTOTACTIC PEPTIDES**(75) Inventors: **Raphael Gorodetsky, Jerusalem (IL); Gerard Marx, N.Y., NY (US)**(73) Assignee: **Medical Research Services and Development Ltd., Jerusalem (IL)**

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: 09/487,790

(22) Filed: **Jan. 20, 2000****Related U.S. Application Data**

(63) Continuation-in-part of application No. 09/084,371, filed on May 27, 1998, now abandoned.

(51) **Int. Cl.****A61K 38/00** (2006.01)**G01N 33/53** (2006.01)(52) **U.S. Cl.** **530/300; 514/2; 424/278.1; 435/7.1**(58) **Field of Classification Search** **530/300, 530/350; 514/2; 424/278.1; 435/7.1**

See application file for complete search history.

(56) **References Cited****U.S. PATENT DOCUMENTS**

4,455,290 A	6/1984	Olexa et al.	424/1.1
5,292,362 A	3/1994	Bass et al.	106/124
5,428,014 A	6/1995	Labroo et al.	514/12
5,473,051 A	12/1995	Altieri et al.	530/382
5,599,790 A	2/1997	Altieri et al.	514/8
5,639,940 A	6/1997	Garner et al.	800/2
5,939,385 A	8/1999	Labroo et al.	514/12
6,083,902 A	7/2000	Cederholm-Williams	514/2
2004/0126758 A1	7/2004	Marx et al.	435/6

FOREIGN PATENT DOCUMENTSWO WO 95/23868 * 9/1995
WO WO 9961041 A1 * 12/1999**OTHER PUBLICATIONS**Watt, K. W. K. et al. (1979) Amino acid sequence of the beta chain of human fibrinogen. *Biochemistry*, vol. 18, pp. 68-76.*
Koopman, J. et al. (1992) Abnormal fibrinogens Umuiden (B beta Arg14—Cys) and Nijmegen (B beta Arg44—Cys) form disulfide-linked fibrinogen-albumin complexes. *Proc. Natl. Acad. Sci. U.S.A.* vol. 89, pp. 3478-3482.*Attachment 1: sequence alignment, pp. 1-3.*
Pandya et al. (1985) Conservation of human fibrinogen conformation after cleavage of the B beta chain NH2 terminus. *J. Biol. Chem.* vol. 260, pp. 2994-3000.*Blumenstein et al. (1992) A beta-turn is present in the 392-411 segment of the human fibrinogen gamma-chain. Effects of structural changes in this segment on affinity to antibody 4A5. *Biochemistry*, vol. 31, pp. 10692-10698.*Henschen et al. (1983) Covalent structure of fibrinogen. *Ann. N. Y. Acad. Sci.* vol. 408, pp. 28-43.*Duga et al. (2000) Missense mutations in the human beta fibrinogen gene cause congenital afibrinogenemia by impairing fibrinogen secretion. *Blood*, vol. 95, pp. 1336-1341.*Yee et al. (1997) Crystal structure of a 30 kDa C-terminal fragment from the gamma chain of human fibrinogen. *Structure*, vol. 5, pp. 125-138.*

Henschen et al. (1980) human fibrinogen sequence, sulfur bridge, glycosylation and some structural variants, in "Protides of the biological fluids" Proc. 28th Colloq., Peeters, H., ed., pp. 51-56.*

Mayo et al. (1990) ¹H NMR sequential assignments and secondary structure analysis of human fibrinogen gamma-chain C-terminal residues 385-411. *Biochemistry*, vol. 29, pp. 3277-3286.*David R. Phillips et al., XP-002218130 "The Platelet Membrane Glycoprotein IIb-IIIa Complex", *The Journal of The American Society of Hematology*, Blood, vol. 71, No. 4, pp. 831-843 (1988).C.J. Nieman et al., XP-001118065, "A Colourimetric Enzyme-Linked Sandwich Assay For The Detection Of Human Platelets Bound To A Fibrinogen-Coated Surface", *Thrombosis Research*, vol. 62, pp. 189-197 (1991).Yiping Fu et al., XP-002218053 "Fibrinogen α Genes: Conservation of Bipartite Transcripts and Carboxy-Terminal-Extended α Subunits in Vertebrates", *GENOMICS*, vol. 30, pp. 71-76 (1995).W. D. Thompson et al., XP-000983610, "Angiogenic Activity Of Fibrin Degradation Products Is Located In Fibrin Fragment E", Department of Pathology and Clinical Biochemistry, *Journal Of P. Pathology*, vol. 168, pp. 47-53 (1992).Dominic W. Chung et al., "Characterization of Complementary Deoxyribonucleic Acid and Genomic Deoxyribonucleic Acid for the β Chain of Human Fibrinogen", *American Chemical Society, Biochemistry*, vol. 22, pp. 3244-3250 (1983).Michael Blumenstein et al., "A β -Turn Is Present in the 392-411 Segment of the Human Fibrinogen γ -Chain. Effects of Structural Changes in This Segment on Affinity to Antibody 4A5", *American Chemical Society, Biochemistry*, vol. 31, pp. 10692-10698 (1992).Yiping Fu et al., "Carboxy-Terminal-Extended Variant of the Human Fibrinogen α Subunit: A Novel Exon Conferring Marked Homology to β and γ Subunits", *American Chemical Society, Biochemistry*, vol. 31, pp. 11968-11972 (1992).Cezary Watala et al., "Microenvironmental changes in platelet membranes induced by the interaction of fibrinogen-derived peptide ligands with platelet integrins", *Eur. J. Biochem.* vol. 235, pp. 281-288 (1996).

* cited by examiner

Primary Examiner—Jon Weber

Assistant Examiner—Samuel Wei Liu

(74) Attorney, Agent, or Firm—Winston & Strawn LLP

(57)

ABSTRACT

This invention is related to a novel peptide consisting of the amino acid sequence of SEQ ID NO.1, and a pharmaceutical composition comprising the peptide thereof.

4 Claims, 7 Drawing Sheets

Hadasit